MicroRNA and siRNA: Mechanisms, Functions, and Applications

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to Small Non-Coding RNAs

What Are Small Non-Coding RNAs?

Small non-coding RNAs (sncRNAs) are a class of RNA molecules typically 18–30 nucleotides in length that do not encode proteins but instead regulate gene expression at the post-transcriptional level. Two major classes dominate this field: microRNAs (miRNAs) and small interfering RNAs (siRNAs). Both function by guiding the RNA-induced silencing complex (RISC) to complementary messenger RNA (mRNA) targets, resulting in gene silencing. Despite their mechanistic similarities, miRNAs and siRNAs differ fundamentally in their origins, biogenesis pathways, and the degree of complementarity required for target recognition.

The discovery of these molecules transformed molecular biology. In 1993, Victor Ambros and colleagues identified the first miRNA, lin-4, in Caenorhabditis elegans, where it controlled developmental timing by repressing the lin-14 gene. This finding was initially considered a worm-specific curiosity. The field expanded dramatically in 1998 when Andrew Fire and Craig Mello demonstrated that double-stranded RNA (dsRNA) could trigger potent sequence-specific gene silencing in C. elegans—a phenomenon they termed RNA interference (RNAi). The subsequent identification of siRNAs as the mediators of RNAi, and the realization that miRNAs are widespread across animals, plants, and viruses, established these molecules as central regulators of gene expression.

Discovery of microRNA and siRNA

The historical trajectory of miRNA and siRNA research reveals two parallel paths converging on a shared molecular machinery. The lin-4 discovery in 1993 was followed by the identification of let-7 in 2000, which was conserved across bilaterian animals, suggesting that miRNA regulation is an ancient and widespread mechanism. Meanwhile, RNAi was recognized as a conserved antiviral defense and gene regulatory system in plants, fungi, and animals. The 2006 Nobel Prize in Physiology or Medicine awarded to Fire and Mello recognized the fundamental importance of RNAi. Today, miRNAs are known to regulate over 60% of human protein-coding genes, while siRNAs have become indispensable tools for gene function studies and hold promise as therapeutic agents.

Biogenesis of microRNA and siRNA

microRNA Biogenesis Pathway

miRNA biogenesis is a multi-step process that begins in the nucleus and concludes in the cytoplasm. The pathway involves two RNase III enzymes—Drosha and Dicer—and the RISC-loading machinery.

1. Transcription: miRNA genes are transcribed primarily by RNA polymerase II, producing primary miRNAs (pri-miRNAs) that are several kilobases long. These transcripts contain a characteristic hairpin structure of approximately 70–100 nucleotides, with a 5′ cap and a 3′ poly(A) tail. Some miRNA genes are located within introns of protein-coding genes and are transcribed as part of the host gene's pre-mRNA.

1. Nuclear processing: The pri-miRNA is recognized by the Microprocessor complex, which consists of the RNase III enzyme Drosha and its cofactor DGCR8 (DiGeorge syndrome critical region 8). DGCR8 binds to the junction between the single-stranded RNA and the double-stranded stem of the hairpin, positioning Drosha to cleave approximately 11 base pairs from the base of the stem. This cleavage releases a ~60–70 nucleotide precursor miRNA (pre-miRNA) with a 2-nucleotide 3′ overhang—a hallmark of RNase III cleavage.

1. Nuclear export: The pre-miRNA is exported to the cytoplasm by Exportin-5 in a Ran-GTP-dependent manner. Exportin-5 recognizes the 2-nucleotide 3′ overhang and the double-stranded stem, ensuring that only properly processed pre-miRNAs leave the nucleus.

1. Cytoplasmic processing: In the cytoplasm, the pre-miRNA is cleaved by Dicer, another RNase III enzyme. Dicer, in complex with the double-stranded RNA-binding protein TRBP (TAR RNA-binding protein), removes the terminal loop, producing a mature miRNA duplex of approximately 21–23 nucleotides. This duplex consists of the guide strand (the mature miRNA) and the passenger strand (miRNA*).

1. RISC loading: The miRNA duplex is loaded into the Argonaute (Ago) protein, the core component of RISC. Ago proteins contain four domains: N-terminal, PAZ (which binds the 3′ end), MID (which binds the 5′ phosphate), and PIWI (which provides endonuclease activity). During loading, the passenger strand is typically degraded, while the guide strand remains associated with Ago. Strand selection is governed by thermodynamic stability: the strand with the less stable 5′ end is preferentially retained as the guide strand.

siRNA Biogenesis Pathway

siRNA biogenesis differs from miRNA production in several key aspects. siRNAs are derived from exogenous double-stranded RNA (dsRNA) rather than from endogenous hairpin transcripts.

1. Source of dsRNA: Exogenous dsRNA can originate from viral replication intermediates, transposon-derived transcripts, or experimentally introduced synthetic dsRNA. In the laboratory, siRNAs are typically produced as 21-nucleotide duplexes with 2-nucleotide 3′ overhangs, mimicking the natural products of Dicer cleavage.

1. Dicer processing: Long dsRNA molecules are cleaved by Dicer into siRNA duplexes of 21–23 nucleotides. Dicer recognizes the ends of the dsRNA and processes it processively, generating a population of siRNAs with distinct sequences covering the entire length of the original dsRNA. This is in contrast to miRNA processing, where Dicer acts on a single defined hairpin substrate.

1. RISC loading: The siRNA duplex is loaded into Ago2, the only human Ago protein with endonuclease activity. The passenger strand is cleaved by Ago2 and subsequently degraded, while the guide strand remains in RISC. For synthetic siRNAs, the guide strand is designed to be complementary to the target mRNA.

1. Amplification (in some organisms): In C. elegans and plants, siRNAs can be amplified by RNA-dependent RNA polymerases (RdRPs), generating secondary siRNAs that enhance the silencing signal. This amplification does not occur in mammals, which limits the duration of siRNA-mediated silencing in these organisms.

The key distinction is that miRNA biogenesis requires Drosha in the nucleus, while siRNA biogenesis from exogenous dsRNA occurs entirely in the cytoplasm. For a more detailed comparison of these pathways, see Small RNA vs Microrna.

Mechanism of Gene Silencing

RISC Assembly and Target Recognition

The RNA-induced silencing complex (RISC) is the effector machinery for both miRNA- and siRNA-mediated silencing. The minimal RISC consists of an Argonaute protein bound to a guide RNA. In humans, there are four Ago proteins (Ago1–4), with Ago2 being the only one possessing catalytic endonuclease activity.

RISC assembly proceeds through several steps:

1. Guide RNA loading: The small RNA duplex is loaded into Ago with the help of the chaperone proteins Hsp70 and Hsp90, which maintain Ago in an open conformation. The MID domain of Ago binds the 5′ phosphate of the guide strand, while the PAZ domain binds the 3′ end.

1. Passenger strand removal: For siRNAs, Ago2 cleaves the passenger strand, facilitating its release. For miRNAs, the passenger strand is typically unwound and degraded without cleavage, particularly when the duplex has mismatches.

1. RISC maturation: The mature RISC contains the guide strand positioned such that nucleotides 2–8 (the "seed region") are exposed and available for base pairing with target mRNAs.

Target recognition is governed by complementarity between the guide strand and the mRNA. The seed region (nucleotides 2–8) is the primary determinant of target specificity. For miRNAs, partial complementarity, particularly in the seed region, is sufficient for target recognition. This allows a single miRNA to regulate hundreds of different mRNAs. For siRNAs, full complementarity across the entire 21-nucleotide sequence is typically required for efficient silencing.

Translational Repression vs. mRNA Cleavage

The outcome of RISC-target interaction depends on the degree of complementarity:

Translational repression (miRNA mode): When the guide strand has partial complementarity to the target mRNA, typically with mismatches in the central region, RISC mediates translational repression. The mechanisms include:

• Inhibition of translation initiation: Ago2 can compete with eIF4E for binding to the mRNA 5′ cap, preventing ribosome recruitment.
• Inhibition of translation elongation: Ribosomes may stall or detach during elongation.
• mRNA deadenylation and destabilization: GW182 proteins, which associate with Ago, recruit the CCR4-NOT deadenylase complex, leading to poly(A) tail shortening and subsequent mRNA degradation. This is now recognized as the predominant mechanism of miRNA-mediated repression in mammals, accounting for the majority of target downregulation.

mRNA cleavage (siRNA mode): When the guide strand has full complementarity to the target mRNA, Ago2 cleaves the mRNA at a specific position—between nucleotides 10 and 11 relative to the 5′ end of the guide strand. This cleavage generates a 5′ fragment with a 3′ hydroxyl group and a 3′ fragment with a 5′ phosphate. The cleaved mRNA is subsequently degraded by exonucleases, leading to rapid and irreversible silencing.

The distinction between these two modes is not absolute. Some miRNAs can direct mRNA cleavage when they encounter targets with perfect complementarity, and some siRNAs can mediate translational repression when mismatches exist. However, the physiological relevance of each mode is determined by the natural complementarity between the guide RNA and its targets.

Functions of microRNA in Gene Regulation

microRNA in Development and Homeostasis

miRNAs are master regulators of gene expression programs, fine-tuning the expression of thousands of genes. Their roles in development are particularly well documented:

Developmental timing: The founding members of the miRNA family, lin-4 and let-7, control the timing of larval development in C. elegans. Let-7 is conserved across bilaterians and regulates genes involved in cell proliferation and differentiation.

Tissue-specific expression: Many miRNAs are expressed in a tissue-specific manner. For example, miR-122 constitutes approximately 70% of all miRNAs in the adult liver and regulates cholesterol metabolism and hepatitis C virus replication. miR-1 and miR-133 are muscle-specific and regulate myoblast proliferation and differentiation.

Cell differentiation: miRNAs promote or maintain differentiated states by repressing genes associated with pluripotency or alternative cell fates. For instance, miR-124 is neuron-specific and promotes neuronal differentiation by targeting anti-neuronal genes. The miR-302/367 cluster is highly expressed in embryonic stem cells and helps maintain pluripotency.

Apoptosis: Several miRNAs regulate programmed cell death. The miR-15a/miR-16-1 cluster targets the anti-apoptotic protein BCL2, and its deletion is associated with chronic lymphocytic leukemia. Conversely, miR-21 is anti-apoptotic and is upregulated in many cancers.

Homeostatic regulation: miRNAs participate in feedback and feed-forward loops that stabilize gene expression. For example, miR-7 and miR-375 regulate insulin secretion in pancreatic β-cells, while miR-208a regulates cardiac stress responses.

microRNA Dysregulation in Disease

miRNA dysregulation is a hallmark of many diseases, particularly cancer:

Oncogenic miRNAs (oncomiRs): Some miRNAs are overexpressed in cancers and promote tumorigenesis. miR-21 is overexpressed in most solid tumors and targets tumor suppressor genes such as PTEN and PDCD4. The miR-17-92 cluster is amplified in B-cell lymphomas and promotes cell proliferation.

Tumor suppressor miRNAs: Other miRNAs are downregulated in cancers and normally suppress tumor formation. The let-7 family targets RAS and MYC oncogenes and is frequently downregulated in lung cancer. miR-34a is a direct transcriptional target of p53 and induces apoptosis and cell cycle arrest.

Diagnostic and prognostic biomarkers: miRNAs are stable in blood and other body fluids, making them attractive biomarkers. Circulating miR-21 levels correlate with tumor burden in several cancers, and miR-122 levels in serum indicate liver injury.

Other diseases: miRNA dysregulation contributes to cardiovascular disease (miR-208, miR-133), neurological disorders (miR-132 in Alzheimer's disease), and metabolic diseases (miR-33 in cholesterol metabolism).

The ability of a single miRNA to regulate multiple targets means that miRNA dysregulation can have widespread effects on cellular pathways, explaining their prominent roles in complex diseases.

Functions of siRNA in Defense and Therapeutics

siRNA in Antiviral Immunity

In plants, invertebrates, and fungi, siRNAs serve as a primary antiviral defense mechanism:

Viral dsRNA recognition: During viral replication, dsRNA intermediates are produced. These are recognized by Dicer and processed into viral siRNAs (vsiRNAs).

Viral genome targeting: The vsiRNAs guide RISC to viral mRNAs, leading to their cleavage and degradation. This effectively limits viral replication and spread.

Systemic silencing: In plants, the silencing signal can spread systemically through plasmodesmata and the phloem, providing organism-wide antiviral immunity.

Transposon silencing: In the germline of animals, siRNAs derived from transposon transcripts silence transposable elements, protecting genome integrity. In C. elegans, the Piwi-interacting RNA (piRNA) pathway, a related small RNA system, cooperates with siRNAs in this process.

In mammals, the antiviral siRNA pathway has been largely replaced by the interferon response, which provides a more generalized antiviral defense. However, the RNAi machinery remains functional and can be harnessed experimentally.

siRNA in Research and Medicine

The ability to design siRNAs against any gene of interest has made them indispensable research tools:

Gene knockdown: Synthetic siRNAs can be introduced into cells to achieve transient gene knockdown. This allows researchers to study gene function by observing the phenotype resulting from reduced gene expression. The process of siRNA knockdown typically results in 70–90% reduction in target mRNA levels within 24–72 hours.

High-throughput screening: siRNA libraries targeting the entire genome enable systematic loss-of-function screens. These screens have identified genes involved in cell viability, drug resistance, and viral infection.

Therapeutic applications: Several siRNA-based drugs have been developed or are in clinical trials:

• Patisiran (Onpattro): Approved by the FDA in 2018 for hereditary transthyretin-mediated amyloidosis. This lipid nanoparticle-formulated siRNA targets transthyretin mRNA in the liver, reducing amyloid deposits.
• Givosiran (Givlaari): Approved in 2019 for acute hepatic porphyria, targeting aminolevulinate synthase 1 (ALAS1).
• Inclisiran (Leqvio): Approved in 2021 for hypercholesterolemia, targeting PCSK9 to lower LDL cholesterol.

These successes have validated the siRNA drug approach. The siRNA therapy field continues to expand, with ongoing trials for conditions ranging from cancer to genetic disorders.

Delivery considerations: Effective siRNA transfection requires delivery vehicles that protect the siRNA from nucleases and facilitate cellular uptake. Common approaches include lipid nanoparticles, polymer-based carriers, and conjugation to targeting ligands such as GalNAc for liver-specific delivery.

Methods to Study microRNA and siRNA

Experimental Detection and Quantification

Several methods are available for detecting and quantifying miRNAs and siRNAs:

Quantitative reverse transcription PCR (qRT-PCR): This is the gold standard for validating miRNA expression. Because miRNAs are too short for conventional primer design, stem-loop RT primers are used. The protocol involves:

1. Reverse transcription using a stem-loop primer specific to the miRNA, typically at 16°C for 30 minutes followed by 42°C for 30 minutes.
2. Quantitative PCR using a miRNA-specific forward primer and a universal reverse primer, with SYBR Green or TaqMan probes.
3. Normalization using small nuclear RNAs such as U6 or snoRNAs.

Microarrays: Microarrays allow simultaneous profiling of hundreds of miRNAs. Total RNA is labeled and hybridized to arrays containing probes complementary to known miRNAs. This method is useful for discovery but has limited dynamic range and cannot detect novel miRNAs.

High-throughput sequencing (small RNA-seq): This method provides comprehensive and unbiased profiling. The workflow involves:

1. Size selection of small RNAs (18–30 nucleotides) by gel electrophoresis or column purification.
2. Ligation of 3′ and 5′ adapters.
3. Reverse transcription and PCR amplification (typically 15–18 cycles).
4. Sequencing on platforms such as Illumina, generating millions of reads.
5. Bioinformatic analysis to map reads to known miRNAs and identify novel miRNAs.

Northern blotting: This classical method detects specific miRNAs using labeled probes. It is less sensitive than qPCR but provides information about RNA size and is useful for validating novel miRNAs.

Reporter assays: To test whether a specific miRNA regulates a target gene, a luciferase reporter construct containing the 3′ untranslated region (UTR) of the target is used. Cells are co-transfected with the reporter and a miRNA mimic or inhibitor. Reduced luciferase activity indicates miRNA-mediated repression. For siRNA validation, western blotting is used to confirm protein knockdown.

Bioinformatics Tools for Target Prediction

Computational prediction of miRNA targets is essential because experimental validation is time-consuming. Key tools include:

TargetScan: Predicts miRNA targets based on seed region complementarity, evolutionary conservation, and thermodynamic stability. It ranks targets by context scores that consider features such as AU content and position within the 3′ UTR.

miRanda: Uses a combination of sequence complementarity and thermodynamic stability to predict targets.

DIANA-microT: Incorporates conserved and non-conserved target sites and considers multiple binding sites in the same UTR.

RNAhybrid: Predicts the minimum free energy of miRNA-target duplexes.

For siRNA design, algorithms such as those described in Design siRNA consider:

• GC content (optimal 30–52%)
• Absence of internal repeats or hairpins
• Position-specific nucleotide preferences
• Off-target potential (seed region matches to unintended mRNAs)

Common Pitfalls and Misconceptions

Key Differences to Remember

Students frequently confuse miRNAs and siRNAs. The critical distinctions are:

For a more detailed comparison, see siRNA and miRNA.

Experimental Pitfalls

Several common errors compromise siRNA and miRNA experiments:

Off-target effects: siRNAs can silence unintended genes through partial seed region complementarity, mimicking miRNA-like behavior. This is a major source of false positives in knockdown experiments. Mitigation strategies include:

• Using multiple independent siRNAs targeting the same gene.
• Using lower siRNA concentrations (typically 1–10 nM).
• Performing rescue experiments with siRNA-resistant overexpression constructs.

Transfection toxicity: Lipid-based transfection reagents can be cytotoxic. Optimizing cell density, reagent-to-siRNA ratios, and incubation times is essential. Typically, 50–70% confluency at transfection and 10–50 nM siRNA are recommended starting points.

Insufficient knockdown verification: Confirming knockdown at both mRNA (qRT-PCR) and protein (western blot) levels is essential. mRNA knockdown does not always correlate with protein knockdown due to protein stability.

Misinterpreting miRNA target validation: A luciferase reporter assay showing repression does not prove physiological relevance. Mutation of the predicted binding site should abolish repression, and endogenous target levels should correlate inversely with miRNA expression.

Ignoring miRNA strand selection: Both arms of a pre-miRNA can generate functional miRNAs (5p and 3p strands). The relative abundance of each strand varies by tissue and condition, and both should be considered.

Summary and Practical Takeaways

Quick Comparison Table

Exam Tips

1. Remember the "D" enzymes: Drosha (nuclear) and Dicer (cytoplasmic). Both are RNase III enzymes that produce 2-nucleotide 3′ overhangs.
2. The seed region (nucleotides 2–8) is the most important concept for miRNA target recognition.
3. Ago2 is the only human Argonaute with slicer activity—this is why siRNAs require Ago2 for mRNA cleavage.
4. The passenger strand is degraded; only the guide strand enters RISC.
5. miRNA-mediated repression in mammals is primarily through mRNA destabilization (deadenylation), not translational inhibition.
6. siRNAs are used experimentally because they can be designed against any gene; miRNAs are endogenous regulators.

Frequently Asked Questions

What is the difference between microRNA and siRNA?

The primary differences are origin and mechanism. microRNAs are endogenous, genome-encoded molecules processed from hairpin precursors by Drosha and Dicer. They typically have partial complementarity to their targets and repress translation or promote mRNA destabilization. siRNAs are exogenous in origin, derived from long double-stranded RNA, processed by Dicer alone, and require full complementarity to direct mRNA cleavage by Ago2.

What is the function of microRNA and siRNA?

microRNAs regulate gene expression during development, differentiation, apoptosis, and homeostasis. They fine-tune protein output by repressing target mRNAs. siRNAs function in antiviral defense in plants and invertebrates and serve as experimental tools for gene knockdown. In medicine, siRNAs are being developed as therapeutic agents to silence disease-causing genes.

How do microRNA and siRNA work?

Both function through the RNA-induced silencing complex (RISC). The guide strand is loaded into an Argonaute protein, and the complex recognizes target mRNAs through base complementarity. With partial complementarity (miRNA mode), the complex represses translation and promotes mRNA degradation. With full complementarity (siRNA mode), Ago2 cleaves the mRNA, leading to its rapid degradation.

Why is siRNA important?

siRNA is important for three reasons: it is a natural antiviral defense mechanism in many organisms; it is a powerful experimental tool for studying gene function through knockdown; and it has therapeutic potential, with several FDA-approved drugs demonstrating clinical efficacy.

Are microRNA and siRNA the same?

No. Although they share the same length, use the same RISC machinery, and both silence genes, they differ in biogenesis (endogenous vs. exogenous), processing enzymes (Drosha + Dicer vs. Dicer alone), target complementarity (partial vs. full), and biological roles (gene regulation vs. defense/tool).

What is RNA interference?

RNA interference (RNAi) is a biological process in which double-stranded RNA triggers sequence-specific gene silencing. It encompasses both miRNA-mediated regulation and siRNA-mediated mRNA cleavage. The pathway involves Dicer processing of dsRNA, loading of small RNAs into RISC, and subsequent target mRNA repression or cleavage. RNAi was first described in C. elegans by Fire and Mello in 1998 and is now a fundamental tool in molecular biology.

Key Takeaways

• microRNAs and siRNAs are both ~21–23 nucleotide small non-coding RNAs that guide RISC to target mRNAs, but they differ in origin, biogenesis, and mechanism of action.
• miRNA biogenesis requires Drosha in the nucleus and Dicer in the cytoplasm; siRNA biogenesis from exogenous dsRNA requires only Dicer.
• The seed region (nucleotides 2–8) of the guide strand is critical for target recognition; partial complementarity leads to translational repression and mRNA destabilization, while full complementarity leads to Ago2-mediated mRNA cleavage.
• miRNAs regulate over 60% of human protein-coding genes and are essential for development, differentiation, and homeostasis; their dysregulation contributes to cancer and other diseases.
• siRNAs are natural antiviral defenses in plants and invertebrates and are powerful experimental tools for gene knockdown in mammalian cells.
• siRNA-based therapeutics have been clinically validated, with drugs such as patisiran and inclisiran approved for human use.
• Common experimental pitfalls include off-target effects, transfection toxicity, and failure to verify knockdown at the protein level; multiple independent siRNAs and proper controls are essential for reliable results.

Further Reading

• Arvey A et al. Target mRNA abundance dilutes microRNA and siRNA activity. Molecular systems biology. 2010. PubMed 20404830
• Jiang Z et al. Rational design of microRNA-siRNA chimeras for multifunctional target suppression. RNA (New York, N.Y.). 2013. PubMed 24145823
• Fjose A, Zhao XF. Inhibition of the microRNA pathway in zebrafish by siRNA. Methods in molecular biology (Clifton, N.J.). 2010. PubMed 20387153
• Lederman L. siRNA and microRNA. BioTechniques. 2009. PubMed 19459275
• Laitala-Leinonen T. Update on the development of microRNA and siRNA molecules as regulators of cell physiology. Recent patents on DNA & gene sequences. 2010. PubMed 20550514
• Sun Y et al. Osteoblast-Targeting-Peptide Modified Nanoparticle for siRNA/microRNA Delivery. ACS nano. 2016. PubMed 27176123

Related Clinical & Scientific Guides

• MAPK Pathway: Mechanism, Function, and Clinical Relevance
• Mammalian Cell Culture Bioreactors: A Practical Guide
• Nucleotide Formation: Biosynthesis and Assembly of DNA/RNA Building Blocks